O que significa “Limpar”?
O animal não carrega a mutação. Não desenvolverá a doença e não vai passar adiante.
Gato Gangliosidose Gm2 em birmanês (GM2-B)
Discover the importance of the DNA test for Gangliosidosis GM2 (GM2) in cats, a genetic disorder affecting Burmese cats. This test helps identify carriers and affected cats, enabling responsible breeding decisions to prevent the spread of this serious condition. Early detection through the GM2 DNA test ensures better health management and improves the quality of life for your Burmese cat. Protect your feline companion by choosing genetic testing for Gangliosidosis GM2 today. Stay informed and keep your Burmese cat healthy with accurate DNA testing. Ensure a healthier future for your pets with reliable GM2 screening.
Abreviatura: GM2-B
Mutação analisada: HEXB c.1244-8_1250del
Herança: Autossômico Recessivo
Acrônimo
GM2-B
Frequência observada
Gravidade clínica
Classificação clínica
Doenças Metabólicas
Mutação analisada
HEXB c.1244-8_1250del
Modo de herança
Autossômico Recessivo
Resumo do teste:
Gangliosidosis GM2 is a genetic disorder that affects cats, caused by a deficiency in the enzyme needed to break down certain fats in the body. DNA testing can identify carriers and affected cats early, helping breeders avoid passing the disease to offspring. This test is important for maintaining healthy breeding lines and preventing the spread of GM2 gangliosidosis. Early diagnosis through DNA testing allows for better care and management of affected cats. Responsible breeding supported by DNA tests improves the overall health of the feline population.
Disponível no pacote: Basic
Este teste de DNA está incluído a partir do nosso pacote Basic - e também faz parte dos packs Basic, Standard, Advanced, Complete.
Ver pacotes de teste de DNA →Escolha o pack que melhor se adapta à sua estratégia de criação ou saúde dos seus animais.
Understanding Gangliosidosis GM2 in Cats
Gangliosidosis GM2 is a genetic disorder that affects the nervous system of cats. This condition is caused by a deficiency in the enzyme Hexosaminidase A (Hex-A), which leads to the accumulation of certain toxic substances in the brain and other tissues. The buildup of these substances can result in severe neurological impairment and a range of clinical symptoms.
Symptoms of Gangliosidosis GM2
Cats affected by Gangliosidosis GM2 may exhibit a variety of symptoms, which can include progressive weakness, lack of coordination, and difficulty in walking. Other signs may involve behavioral changes, such as increased lethargy, seizures, or unusual vocalizations. As the disease progresses, affected cats may experience a decline in their quality of life, leading to a need for supportive care.
Diagnosis of Gangliosidosis GM2
To diagnose Gangliosidosis GM2, veterinarians often conduct a combination of clinical evaluations and genetic testing. The genetic test specifically identifies mutations in the HEXA gene, which is responsible for the production of the Hex-A enzyme. Confirming a diagnosis through genetic testing is crucial for understanding the condition and planning appropriate care for affected animals.
Management and Care for Affected Cats
Currently, there is no cure for Gangliosidosis GM2, and treatment focuses primarily on managing symptoms and providing supportive care. This may include physical therapy, nutritional support, and pain management. Owners of affected cats should work closely with their veterinarians to develop a care plan tailored to the individual needs of their pet.
Importance of Genetic Testing
Genetic testing for Gangliosidosis GM2 is essential for responsible breeding practices. By identifying carriers of the HEXA gene mutation, breeders can make informed decisions to reduce the incidence of this disease in future generations. Additionally, early detection through testing allows for proactive management of affected cats, improving their quality of life.
Conclusão
Gangliosidosis GM2 is a serious genetic disorder that poses significant challenges to affected cats and their owners. Understanding the condition, its symptoms, and the importance of genetic testing can help in managing the disease and making informed decisions regarding breeding practices. With continued research and advancements in veterinary care, there is hope for better outcomes for cats affected by this condition.
Raça reconhecida para o teste: Gangliosidose Gm2 em birmanês (GM2-B)
- Burmese
🧬 Interpretation of genotypes GM2-B
Genótipo
Status
🟡 N/N
Não portador - sem risco
🟡 N/GM2-B
Transportadora - Sem Risco
❌ GM2-B/GM2-B
Afetados - Em risco
FAQ: entendendo a interpretação
Um “transportador” é sério?
Não. O animal é geralmente saudável, mas pode transmitir a mutação ao seu descendência.
E se um animal for “afetado”?
Ele carrega duas cópias mutadas. Os sinais clínicos são esperados dependendo a doença. Não deveria ser criado.
Por que existem diferenças entre homem/mulher?
Algumas doenças estão ligadas ao sexo, pelo que a sua expressão varia dependendo do sexo do animal.
Prever descendência
N/N (nao-portador)
N/GM2-B (Operadora)
GM2-B/GM2-B (Afetado)
Perguntas frequentes sobre testes de DNA
O que este teste de DNA detecta?
This DNA test detects the mutation associated with Gangliosidosis Gm2 In Burmese (GM2-B) in order to identify clear, carrier, or at-risk animals.
Por que testar um animal reprodutor?
Os testes de DNA ajudam os criadores a planejar acasalamentos mais seguros e a reduzir o risco de transmissão da mutação aos descendentes.
Qual é o modo de herança deste teste?
O modo de herança relatado para este teste é Autossômico Recessivo.
Qual mutação é analisada neste teste?
This test analyses the mutation HEXB c.1244-8_1250del.
Um animal portador é necessariamente afetado?
Não necessariamente. A interpretação depende do padrão de herança e do genótipo resultante.
Referências
Bradbury Allison M, Morrison Nancy E, Hwang Misako, Cox Nancy R, Baker Henry J, Martin Douglas R. Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency. Mol Genet Metab. 2009 May;97(1):53-9. doi: 10.1016/j.ymgme.2009.01.003. Epub 2009 Feb 23.